vorinostat has been researched along with Central Nervous System Neoplasm in 2 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Histone deacetylase inhibitors (HDACIs) represent a class of agents that can modulate gene expression to reduce tumor growth, and we and others have noted some antiglioma activity from HDACIs, such as vorinostat, although insufficient to warrant use as monotherapy." | 7.79 | Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage. ( Agostino, NR; DiDomenico, JD; Jane, EP; Pollack, IF; Premkumar, DR, 2013) |
| " Histone deacetylase inhibitors (HDACIs) represent a class of agents that can modulate gene expression to reduce tumor growth, and we and others have noted some antiglioma activity from HDACIs, such as vorinostat, although insufficient to warrant use as monotherapy." | 3.79 | Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage. ( Agostino, NR; DiDomenico, JD; Jane, EP; Pollack, IF; Premkumar, DR, 2013) |
| "Vorinostat was tolerated without serious adverse events by all patients." | 1.91 | Proteostasis Modulation in Germline Missense von Hippel Lindau Disease. ( Alvarez, R; Asuzu, DT; Bugarini, A; Chew, EY; Chittiboina, P; Elkahloun, A; Linehan, M; Lonser, RR; Mandal, D; Maric, D; Mastorakos, P; Mullaney, D; Scott, G; Stoica, S; Yang, C; Zhuang, Z, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chittiboina, P | 1 |
| Mandal, D | 1 |
| Bugarini, A | 1 |
| Asuzu, DT | 1 |
| Mullaney, D | 1 |
| Mastorakos, P | 1 |
| Stoica, S | 1 |
| Alvarez, R | 1 |
| Scott, G | 1 |
| Maric, D | 1 |
| Elkahloun, A | 1 |
| Zhuang, Z | 1 |
| Chew, EY | 1 |
| Yang, C | 1 |
| Linehan, M | 1 |
| Lonser, RR | 1 |
| Premkumar, DR | 1 |
| Jane, EP | 1 |
| Agostino, NR | 1 |
| DiDomenico, JD | 1 |
| Pollack, IF | 1 |
2 other studies available for vorinostat and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Proteostasis Modulation in Germline Missense von Hippel Lindau Disease.
Topics: Biological Products; Central Nervous System Neoplasms; Hemangioblastoma; Humans; Proteostasis; von H | 2023 |
Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulato | 2013 |